Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: INSP stock price vs LLY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LLY's multiple
Needs LLY P/E.
Implied fair value · at INSP's multiple
Needs INSP P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INSP FY 2025 (ended Dec 31, 2025) · LLY FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Inspire Medical Systems, Inc. · implied price per share
Bear
$14.19
Base
$16.69
Bull
$19.20
ELI LILLY AND COMPANY · implied price per share
Bear
$191.97
Base
$225.85
Bull
$259.72
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.04x
1.60x
Net debt / EBITDA
Leverage against operating earnings
-4.05x
1.22x
Cash and equivalents
Liquid reserves on the balance sheet
$308.27M
$7.42B
Total debt
Interest-bearing obligations outstanding
$33.69M
$42.50B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BOSTON SCIENTIFIC CORP
INSP vs BSX
Medtronic plc
INSP vs MDT
ABBOTT LABORATORIES
INSP vs ABT
JOHNSON & JOHNSON
INSP vs JNJ
LivaNova PLC
INSP vs LIVN
Pfizer Inc.
INSP vs PFE
Merck & Co., Inc.
INSP vs MRK
AbbVie Inc.
INSP vs ABBV
Amgen Inc.
INSP vs AMGN
Bristol-Myers Squibb Company
INSP vs BMY
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe INSP can sustain double-digit growth while converting its strong gross margin into materially higher operating leverage, then the stock looks attractive relative to LLY because it trades at a much lower P/E and P/S despite strong balance sheet quality.
INSP trades at 9.6x P/E and 1.5x P/S versus LLY at 52.9x P/E and 17.5x P/S, implying a very large relative valuation discount. The current price of $46.95 sits near the low end of the historical band and far below LLY-implied value, but the spread is partly explained by LLY's much stronger growth and profitability.
Supporting Metrics
